%0 Journal Article %A KUNIO MOCHIZUKI %A MASATAKA KAWAI %A TORU ODATE %A IPPEI TAHARA %A TOMOHIRO INOUE %A KAZUNARI KASAI %A TADAO NAKAZAWA %A TETSUO KONDO %T SMARCB1/INI1 Is Diagnostically Useful in Distinguishing α-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma %D 2018 %R 10.21873/anticanres.13061 %J Anticancer Research %P 6865-6868 %V 38 %N 12 %X Background/Aim: Switch/sucrose non-fermentable (SWI/SNF)-related, matrix-associated, actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1), also named integrase interactor 1, is one of the core subunit proteins in the SWI/SNF ATP-dependent chromatin remodeling complex encoded at chromosomal position 22q11.2. Complete loss of SMARCB1 expression has been reported in various malignant tumors. Immunohistochemistry has demonstrated that SMARCB1 mutation/inactivation correlates well with loss of nuclear SMARCB1 expression. This study investigated SMARCB1 expression in hepatocellular carcinomas (HCCs) and α-fetoprotein (AFP)-producing gastric carcinomas by immunohistochemistry. For comparison, SMARCB1 immunostaining in intrahepatic cholangiocarcinoma (ICC) was also performed. Materials and Methods: Thirty classical HCCs, 30 ICCs and 10 AFP-producing gastric carcinomas were analyzed. Results: Only one case of HCC had focal labeling of SMARCB1 in the nuclei. Twelve cases of ICC were immunopositive for SMARCB1, with either focal or diffuse reactivity. All AFP-producing gastric carcinomas were immunopositive for SMARCB1 in the nuclei, and the reactivity was consistently diffuse. Conclusion: SMARCB1 is a potential marker for distinguishing metastatic AFP-producing gastric carcinoma from HCC. %U https://ar.iiarjournals.org/content/anticanres/38/12/6865.full.pdf